TIDMERGO

Ergomed plc

01 April 2019

PRESS RELEASE

Roy Ovel appointed as Chief Commercial Officer

London, UK - 1 April 2019: Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Roy Ovel as Chief Commercial Officer with immediate effect.

Roy brings to Ergomed over 30 years' experience in international business development with a number of the leading global CROs. This has included roles with larger CROs such as ICON, TFS and Worldwide Clinical Trials as well as with local, specialist CROs. At TFS International, Roy was responsible for global sales and marketing for more than four years, including leadership of the global marketing team.

Roy will join Ergomed's Executive team and will be responsible for global sales and business development activities across the Company's full services offering. This will include a focus on the benefits to customers of bringing together Ergomed's expertise in pharmacovigilance and orphan drug development.

Roy will report directly to Dr Miroslav Reljanović, Executive Chairman of Ergomed.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Roy brings a wealth of experience to Ergomed. He has a proven track record in building commercial success through an understanding of customer's needs and delivering growth. I am confident that operating across the Ergomed business he will make a significant contribution to the Company through the services we provide our clients."

Roy Ovel, Chief Commercial Officer of Ergomed, said: "Ergomed's 20-year track record in full-service, tailored contract clinical development and its strength in pharmacovigilance offer significant benefits to clients across the pharmaceutical industry. I very much look forward to building on the company's success and its position as a leading global CRO."

Enquiries:

 
 Ergomed plc                                      Tel: +44 (0) 1483 402 
                                                   975 
 Miroslav Reljanović (Executive Chairman) 
 Stuart Jackson (Chief Financial Officer) 
 
 Numis Securities Limited                        Tel: +44 (0) 20 7260 1000 
 Freddie Barnfield (Nominated Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for        Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Mary-Jane Elliott               ergomed@consilium-comms.com 
 Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European          Tel: +49 211 5292 5222 
  enquiries 
 Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAZMGFFGMVGLZZ

(END) Dow Jones Newswires

April 01, 2019 02:01 ET (06:01 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.